Warning Labels The Surgeon General’s report led to the Federal ... The efficacy and acceptability of pharmacological ...

Researchers have tested a novel therapeutic concept to treat virus-induced lung failure in patients with severe COVID-19 in a phase 2 clinical trial. The approach may also be applicable to other ...

Label-free biosensor assay detects Toll-like receptor signals and even discriminates between different signaling pathways.

A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...

A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...

New research points to taking melatonin 3 hours before bedtime but some experts say it is still best to take the supplement ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 ...

Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, 2024, compared to a net loss of approximately $11.3 million, or $0.48 per ...

The latest COVID-19 treatment, using an inhibitor of the Fas ligand (FasL), also known as CD95 ligand (CD95L), speeds up ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patien ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Welcome to Tarsus’ Third Quarter 2024 Financial Results ...